Evaluation of effectiveness, safety and cost-benefit of the 23– valent pneumococcal capsular polysaccharide vaccine for HIV-Infected patients. Issue 1 (3rd January 2022)

• Record Type: Journal Article
• Authors: Zou, Xiaobai; He, Jianmei; Zheng, Jun; Liang, Mengran; Gao, Jinjin; Huang, Jianwen; Jiang, Yang; Jiang, Yonglin; Chen, Xi
• Is Part Of: Vaccine. Volume 40:Issue 1(2022)
• Page Start: 37
• Page End: 42
• Publication Date: 2022-01-03
• Subjects: HIV -- 23-valent pneumococcal polysaccharide vaccine -- Streptococcus pneumoniae -- Pneumococcal pneumonia; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2021.11.058
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: Introduction: Due to the lack of understanding of the protective effects and safety of 23-valent pneumococcal polysaccharide vaccine (PPV23) in immune-deficient populations, the vaccination rate of PPV23 among HIV-infected patients is still very low in China. The main objectives of this study were to determine whether the efforts to assess measures for the prevention of pneumococcal pneumonia are still worthwhile, and provide designated vaccination program of HIV-infected persons for government policy based on. Methods: 60 HIV-infected adults in Lanshan county who had never been vaccinated with any pneumococcal vaccine were enrolled in this study, voluntary vaccination of PPV23 and One-year follow-up after vaccination can be completed. Result: 76.67% patients (46/60) had serologic response at 12 months after vaccine, CD4 count(≤500 cells/ul or > 500 cells/ul) and Month from diagnosis to first antiviral therapy (≤1 month or > 1 month) were related to antibody responses (p < 0.05).In this study, PPV23 was well tolerated, no adverse reaction was reported.11 Streptococcus pneumoniae pneumonia (9.17%, 11/120) occurred in the Unvaccinated group and 1 case(1.67%, 1/60)in the vaccination group within one year after vaccination(Fisher's exact probability, P = 0.225). The VE was 81.79%. The per capita benefit was 39.32 dollars, the benefit-cost ratio = 1.19. There are significant statistical differences between the vaccinated group and the non-vaccinated group in outpatient costs (p < 0.05, 95 %CI: 9.29–32.11), Medicine costs (p = 0.017, 95 %CI: 2.47–24.44), and disease related indirect costs (p = 0.038, 95 %CI: 0.93–33.63) within one year of vaccination. Conclusion: Our study results showed that PPV23 can be safely and effectively administered to HIV-1 infected individuals and effectively preventing Streptococcal pneumonia. Considering the cost-benefit of vaccination among HIV-infected persons, as it has been reported in our study, it is necessary to promote the widespread use of the vaccine among HIV-infected persons in the future.